Partner & Licensee Pipeline

Pre-Clinical & Discovery Stage

BB106

Gap

Critical need for more and better PTSD treatment options PTSD costs society billions in health care & lost productivity

Rationale

Address a long felt need for a treatment & ROA designed for the psychiatrist’s office Develop an indication that expands beyond TRD, which is becoming crowded with empathogens & 5HT2A agonists

Market Opportunity

$2.3B global1

1 Coherent Market Research

Why Ketamine?

BB30X

Gap

DMT is the prototypical psychedelic but:

  • Inhaled is too fast and strong. 
  • IV delivery is expensive, & psychiatrists don’t offer IVs
  • Oral dosing requires dangerous MAO inhibitors

Rationale

DMT shows strong potential in mental health if you can control entry, altitude and exit of the experience. Bexson's Sub-Q DMT + pump can manage this gracefully.

Market Opportunity

$1.2B global1

1 Coherent Market Research

Why DMT?

Gap

IV-only infusion treatments are very expensive.4 Requires in-clinic IV administration or very expensive at home services.

Rationale

Moving from IV to SubQ wearable delivery will improve patient safety & convenience. Large cost savings by removing clinic and daily IV services. 505b2 regulatory pathway

Market Opportunity

>$1.5B U.S.5

4 JAMA Network Open. 2022
5 Research and Markets (Dec 2021)

Why Dalbavancin?